PharmaSignal Explainers Why “Approved” Filings Unravel After Central Teams DisengageBy PharmaSignal News DeskDecember 18, 20250
PharmaSignal Explainers Why Global Deal Theses Quietly Die at Affiliate HandoverBy PharmaSignal News DeskDecember 18, 20250
Market Access Clinical Trials Access Lacking in Tested CountriesNovember 20, 2025By PharmaSignal News Desk Clinical trials access remains limited as only 24% of drugs tested in 89 countries are available post-approval.
Deal of the Month Deal of the Month: Deal Signals to note A senior BD execution signal from this month’s most instructive pharma deal.
